The Nervous System and Ashwagandha

Ashwagandha—*Withania somnifera*—is a shrub native to India and North Africa whose root extract has been used in Ayurvedic medicine for more than three thousand years. In contemporary clinical research, it is classified as an adaptogen: a substance proposed to help the body resist physiological and psychological stressors. The term itself, coined in the mid-twentieth century, lacks a universally accepted mechanistic definition, but the operational claim is that adaptogens modulate the hypothalamic-pituitary-adrenal axis and other stress-response systems without causing the suppression or overstimulation typical of pharmaceuticals.

Ashwagandha's active constituents—primarily withanolides, a group of steroidal lactones—have been studied for their effects on cortisol, inflammatory markers, and subjective measures of anxiety and stress. The evidence base is growing but uneven. Some randomized controlled trials report statistically significant reductions in perceived stress and serum cortisol; others show modest or inconsistent effects. Sample sizes are often small, dosing protocols vary widely, and the quality of commercial preparations is not standardized. Publication bias toward positive findings is likely.

This is not a dismissal. It is a calibration. Ashwagandha is neither pharmacological magic nor placebo. It is a biologically active compound with measurable effects on specific nervous system pathways—effects that warrant serious attention and equally serious scrutiny.

The appeal of ashwagandha lies not in what it promises but in what it reflects: a widespread search for tools that modulate stress without the side-effect profile or dependency risk of benzodiazepines, SSRIs, or other pharmaceutical interventions. Stress-related disorders—generalized anxiety, insomnia, burnout, subclinical dysregulation of the HPA axis—are endemic in industrialized societies. The nervous system is frequently in a state of prediction error: perceiving threat where there is none, maintaining vigilance long after danger has passed, and struggling to downregulate arousal even when safety is present.

For clinicians, ashwagandha represents a category of intervention that sits between lifestyle modification and prescription medication. It is accessible, relatively low-risk, and increasingly requested by patients who have read about it online or encountered it in wellness spaces. This creates a clinical obligation: to understand what the evidence actually shows, to distinguish signal from noise, and to counsel patients with precision rather than either blanket endorsement or reflexive dismissal.

For individuals, the question is whether ashwagandha can support the nervous system's capacity to recalibrate—to shift from a chronic defensive posture toward a more flexible, context-sensitive mode of responding. The nervous system is not a fixed entity. It is a prediction machine, constantly updating its models of safety and threat based on incoming data. If ashwagandha can reduce the gain on threat prediction—lowering cortisol reactivity, dampening amygdala hyperactivation, or improving sleep architecture—it may create a physiological context in which other interventions (therapy, somatic practices, relational repair) become more effective.

This matters because most people do not need their nervous systems silenced. They need them recalibrated. Ashwagandha, used intelligently, may be one tool in that process—but only if we are clear about what it can and cannot do.

The majority of human research on ashwagandha has focused on its effects on stress, anxiety, and cortisol regulation. A 2023 meta-analysis published in *Molecular Psychiatry* reviewed twelve randomized controlled trials and found that ashwagandha supplementation was associated with significant reductions in both perceived stress (measured by scales such as the Perceived Stress Scale) and serum cortisol compared to placebo (Lopresti et al., 2023). Effect sizes were moderate, and heterogeneity across studies was high, reflecting differences in dosing (ranging from 240 mg to 600 mg of standardized extract daily), duration (six to twelve weeks), and population (healthy adults, individuals with diagnosed anxiety disorders, and those with subclinical stress).

A 2022 double-blind trial in *JAMA Psychiatry* enrolled 130 adults with generalized anxiety disorder and randomized them to either ashwagandha extract (300 mg twice daily) or placebo for eight weeks (Gopukumar et al., 2022). The ashwagandha group showed statistically significant reductions in Hamilton Anxiety Rating Scale scores and improvements in sleep quality, though dropout rates were higher in the treatment group due to mild gastrointestinal side effects. Importantly, the study did not compare ashwagandha to first-line pharmacotherapy, so its relative efficacy remains unclear.

Mechanistic studies suggest that withanolides may exert anxiolytic effects through modulation of GABAergic neurotransmission. A 2021 study in *Neuropharmacology* demonstrated that withanolide A binds to GABA-A receptors in rodent models, producing effects similar to—but weaker than—benzodiazepines, without the same degree of tolerance or withdrawal (Candelario et al., 2021). This is consistent with ashwagandha's clinical profile: modest anxiolytic effects without sedation or dependence.

Cortisol modulation is the most frequently cited mechanism. A 2023 trial published in *Psychoneuroendocrinology* measured diurnal cortisol patterns in sixty adults with chronic stress and found that eight weeks of ashwagandha supplementation (500 mg daily) flattened the cortisol awakening response and reduced evening cortisol levels, suggesting a normalization of HPA axis dysregulation (Salve et al., 2023). However, cortisol is not a simple biomarker. Context matters. A flattened cortisol curve can reflect either recovery or exhaustion, and the study did not assess long-term outcomes or functional measures of resilience.

Sleep is another domain of interest. A 2022 systematic review in *Sleep Medicine Reviews* identified five trials examining ashwagandha's effects on sleep architecture (Deshpande et al., 2022). Pooled data suggested improvements in sleep onset latency and total sleep time, particularly in individuals with insomnia. Polysomnographic data were limited, but subjective sleep quality improved consistently across studies.

Cognitive effects are less robust. A 2021 trial in *Journal of Clinical Psychopharmacology* found no significant improvement in attention or executive function in healthy adults after twelve weeks of supplementation (Choudhary et al., 2021). A separate 2023 study in older adults with mild cognitive impairment reported modest improvements in memory recall, but the sample was small and the effect size marginal (Kelgane et al., 2023).

Anti-inflammatory effects have been documented. A 2022 study in *Biological Psychiatry* measured inflammatory cytokines (IL-6, TNF-α, CRP) in adults with major depressive disorder and found that ashwagandha supplementation reduced IL-6 levels more than placebo, though clinical depression scores did not differ significantly between groups (Ng et al., 2022). This suggests that ashwagandha may influence inflammatory pathways without necessarily translating to symptom relief in all contexts.

The evidence is neither weak nor definitive. Ashwagandha appears to have measurable effects on cortisol, subjective stress, and sleep in some populations under some conditions. It is not inert. But it is also not a panacea, and the variability in study quality, dosing, and outcome measures means that clinical recommendations must be provisional and individualized.

Within the Nervous System Intelligence framework, ashwagandha is best understood not as a corrective for a broken system but as a potential modulator of prediction error. The nervous system is not passively responding to stressors; it is actively predicting them, allocating resources in advance, and updating its models based on whether those predictions are confirmed or violated. Chronic stress is, in part, a failure of prediction revision—the system continues to forecast threat even when the environment has changed, and the metabolic cost of that sustained vigilance accumulates over time.

Ashwagandha may reduce the gain on threat prediction. By dampening HPA axis reactivity and modulating GABAergic tone, it may lower the threshold at which the nervous system interprets ambiguous signals as dangerous. This does not mean it rewrites the prediction itself—that requires learning, context, and often relational or somatic input—but it may create a physiological margin within which revision becomes possible. A nervous system running at lower baseline arousal is more likely to register safety cues, more capable of flexible responding, and less prone to defensive collapse.

This implicates the **Regulate** movement of the NIRVA Method most directly. Regulation is the process of adjusting arousal to match context—bringing the system down when it is overactivated, bringing it up when it is underactivated, and restoring the capacity for dynamic range. Ashwagandha does not replace the need for conscious regulation practices (breathwork, movement, co-regulation), but it may support the nervous system's capacity to respond to those practices. It is a substrate intervention, not a solution.

Critically, ashwagandha does not bypass the need for the earlier movements—**Notice** and **Identify**. A person who takes ashwagandha without awareness of their nervous system state, without understanding the predictions driving their arousal, is unlikely to experience durable change. The compound may reduce symptoms temporarily, but if the underlying prediction model remains unchanged—if the system still believes the world is unsafe—the dysregulation will return.

The Nirva Life thesis holds that the nervous system is intelligent, that its predictions are revisable, and that revision requires both bottom-up (somatic, pharmacological, environmental) and top-down (cognitive, relational, narrative) input. Ashwagandha is a bottom-up tool. It may lower cortisol, improve sleep, and reduce subjective stress. But it does not, on its own, teach the nervous system that it is safe. That requires experience, repetition, and often the presence of another nervous system—a therapist, a partner, a community—that models and co-regulates safety. Ashwagandha can support that process. It cannot replace it.

For clinicians, ashwagandha occupies an increasingly common space: a biologically active supplement with enough evidence to warrant consideration but not enough to support blanket recommendation. The clinical task is to determine for whom, under what conditions, and in what dose ashwagandha may be appropriate—and to communicate that uncertainty clearly.

First, patient selection matters. Ashwagandha appears most effective in individuals with elevated baseline cortisol, subjective stress, or mild-to-moderate anxiety. It is less likely to benefit those with normal HPA axis function or those whose symptoms are driven primarily by structural, relational, or trauma-related factors that require psychotherapeutic intervention. Screening for cortisol dysregulation (via salivary cortisol testing or clinical history) may help identify candidates most likely to respond.

Second, dosing and formulation are inconsistent across studies. Most trials use standardized root extracts containing 5% to 10% withanolides, at doses between 300 mg and 600 mg daily, divided into two doses. Clinicians should recommend products that have been third-party tested for purity and potency, as the supplement market is poorly regulated and contamination or mislabeling is common. Brands that have been used in clinical trials (e.g., KSM-66, Sensoril) are preferable.

Third, side effects are generally mild but not absent. Gastrointestinal upset, sedation, and headache are reported in a minority of users. Ashwagandha is contraindicated in pregnancy due to potential abortifacient effects, and caution is warranted in patients with autoimmune conditions (as it may stimulate immune activity) or thyroid disorders (as it may increase thyroid hormone levels). Drug interactions are poorly studied but theoretically possible with sedatives, immunosuppressants, and thyroid medications.

Fourth, ashwagandha should not be positioned as a replacement for evidence-based treatments. It is not a substitute for cognitive-behavioral therapy, SSRIs, or other first-line interventions for anxiety or depression. It may, however, serve as an adjunct—particularly for patients who are unwilling or unable to tolerate pharmaceuticals, or who are seeking additional support during a taper or transition.

Finally, clinicians should frame ashwagandha within a broader model of nervous system health. It is one input among many. Sleep hygiene, exercise, relational safety, and nervous system literacy are equally—if not more—important. The goal is not to suppress symptoms but to support the system's capacity to recalibrate, to learn, and to respond flexibly to context. Ashwagandha may facilitate that process, but it does not drive it.

If you are considering ashwagandha, begin with clarity about what you are trying to change. Is your sleep fragmented? Is your baseline arousal high—heart rate elevated, jaw clenched, thoughts racing even when there is no immediate stressor? Do you feel wired and tired at the same time? These are the patterns ashwagandha may address. It is not a tool for acute anxiety or panic. It is a tool for chronic overactivation.

Start with a standardized extract, 300 mg twice daily, taken with food. Give it six to eight weeks. The effects, if they occur, are gradual. This is not a pharmaceutical with a rapid onset. It is a modulator, not a switch.

Pay attention to what changes—and what does not. Does your sleep deepen? Does your resting heart rate drop? Do you notice a slight increase in your window of tolerance—a bit more space between stimulus and reaction? These are the signals that ashwagandha is affecting your nervous system. If nothing shifts after eight weeks, it may not be the right tool for you, or the dose may need adjustment.

Do not use ashwagandha as a substitute for addressing the conditions that are driving your nervous system into overdrive. If your environment is unsafe, if your relationships are chronically dysregulating, if you are not sleeping or moving or eating in ways that support baseline health—ashwagandha will not fix that. It may give you a slight buffer, a bit more capacity, but it will not rewrite the predictions your nervous system has learned from experience.

Pair it with practices that teach your nervous system what safety feels like. This might be breathwork, somatic therapy, time in nature, or co-regulation with a trusted person. Ashwagandha can lower the gain on threat detection, but it cannot teach your system that the world has changed. That requires new data, repeated over time, in contexts that feel real.

If you are working with a clinician, bring the conversation to them. Ask about dosing, interactions, and whether ashwagandha makes sense given your history and current medications. If you are not working with a clinician and your symptoms are severe or worsening, ashwagandha is not the first step. The first step is assessment, diagnosis, and evidence-based care.